Myositis antibody evaluation  

Our focused antibody panel includes only specific antibodies associated with IIM, enabling rapid answers that expedite diagnosis and treatment.

Key testing

• MSAES | Myositis Specific Antibody Evaluation, Serum

Advantages

• Enables early detection of IIM, particularly atypical or severe cases.
• Methodologies were selected to optimize the accuracy and reliability of antibody detection to guide prognosis and tailor disease management.
  • Included antibodies were carefully selected for their direct associations to IIM subtypes.
  • MSAs are essential for differentiating IIM, which include dermatomyositis, polymyositis, inclusion body myositis, necrotizing autoimmune myopathy, and anti-synthetase syndrome.
  • MSAs enable precise phenotyping and stratification of IIM subtypes, providing insights into associated extra muscular disease activity, disease prognosis, and therapeutic responses.
• Reduces diagnostic uncertainty.
• Provides industry-leading time to results of 3–7 days.
• If IFA patterns indicate signal recognition particle (SRP) antibodies, then SRP IFA titer and SRP54 immunoblot will be performed at an additional charge.

---

References

1. Chinoy H, Fertig N, Oddis CV, Ollier WE, Cooper RG. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis. 2007;66(10):1345-1349
2. Betteridge Z, McHugh N. Myositis-specific autoantibodies: an important tool to support the diagnosis of myositis. J Intern Med. 2016;280(1):8-23